Home › Compound Library › Semaglutide (Ozempic/Wegovy)

Semaglutide (Ozempic/Wegovy)

Peptideprescriptionsubcutaneous · inferred

GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Binds albumin for extended half-life of ~168 hours (7 days), enabling once-weekly dosing. Reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion.

Projected serum levels — 0.50 mg, weekly

Semaglutide (Ozempic/Wegovy)
Semaglutide (Ozempic/Wegovy) modeled serum levels, 0.50 mg weekly over 56 days Population-based pharmacokinetic estimate. Steady state reached after approximately 21 days. 0 0.25 0.50 0.75 1 Day 0 Day 14 Day 28 Day 42 Day 56 Time on a regular schedule ≈ steady state · day 21
Semaglutide (Ozempic/Wegovy) modeled serum levels with a loading dose of 0.99 mg, then 0.50 mg weekly The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 14 Day 28 Day 42 Day 56 Time on a regular schedule

Maintenance schedule: 0.50 mg weekly (subcutaneous).

Loading schedule: 0.99 mg on day 1, then 0.50 mg weekly — reaching therapeutic levels sooner.

Modeled steady state after ~21 days: peak ≈ 0.21 mg, trough ≈ 0.12 mg body load. Population-based estimate over 56 days for a 0.50 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
7 days
Common dose
0.50 mg
Suggested maximum
2.4 mg/day
Reference dose range
0.25–2.4 mg (single dose)
Suggested cadence
weekly
Validated against
0.50 mg sc — Cmax 0.015 mg/L at 24 h

Documented interactions

  • watch
    Dulaglutide (Trulicity) + Semaglutide (Ozempic/Wegovy) Stacked effects

    Dulaglutide (Trulicity) and Semaglutide (Ozempic/Wegovy) both push the glp1 receptor in the same direction.

  • watch
    Liraglutide (Victoza/Saxenda) + Semaglutide (Ozempic/Wegovy) Stacked effects

    Liraglutide (Victoza/Saxenda) and Semaglutide (Ozempic/Wegovy) both push the glp1 receptor in the same direction.

  • watch
    Retatrutide (Reta) + Semaglutide (Ozempic/Wegovy) Stacked effects

    Retatrutide (Reta) and Semaglutide (Ozempic/Wegovy) both push the glp1 receptor in the same direction.

  • watch
    Sitagliptin (Januvia) + Semaglutide (Ozempic/Wegovy) Stacked effects

    Semaglutide (Ozempic/Wegovy) and Sitagliptin (Januvia) both push the glp1 receptor in the same direction.

  • watch
    Tirzepatide (Mounjaro/Zepbound) + Semaglutide (Ozempic/Wegovy) Stacked effects

    Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound) both push the glp1 receptor in the same direction.

Serum checks 5 modeled interaction pairings for semaglutide (ozempic/wegovy) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) Wilding JPH et al. · New England Journal of Medicine, 2021 DOI

    Landmark phase 3 trial showing 2.4 mg weekly semaglutide produced 14.9% mean body weight loss vs 2.4% with placebo over 68 weeks in adults with obesity.

  2. Pharmacokinetics and Clinical Implications of Semaglutide: A New GLP-1 Receptor Agonist Hall S et al. · Clinical Pharmacokinetics, 2018 DOI

    Comprehensive pharmacokinetic review establishing semaglutide half-life of ~1 week (145-168 h), high albumin binding (>99%), and dose-proportional exposure supporting once-weekly administration.

  3. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) Marso SP et al. · New England Journal of Medicine, 2016 DOI

    Pivotal cardiovascular outcomes trial demonstrating semaglutide significantly reduced major adverse cardiovascular events by 26% compared to placebo in type 2 diabetes patients at high CV risk.

3 published studies referenced in the app, each with a plain-language summary.